Engineering pH-Dependent Orally Disintegrating Tablets for Modified Indomethacin Release: A Polymer-Based Approach
- PMID: 40140231
- DOI: 10.1208/s12249-025-03082-y
Engineering pH-Dependent Orally Disintegrating Tablets for Modified Indomethacin Release: A Polymer-Based Approach
Abstract
The application of pH-sensitive polymers has been widely explored in pharmaceutical industry because of their versatile properties. This work aims to delay the release of indomethacin (IND), a commonly used anti-inflammatory drug, using a pH-dependent polymer within orally disintegrating tablets (ODTs) and to investigate the effect of the polymer particle size on the ODTs. When developing delayed-release formulations for orally disintegrating tablets (ODTs), it's essential to balance the pellet's matrix properties to maintain integrity and delayed release. Different sizes of Eudragit L100 were used to create IND-containing pellets via extrusion spheronization, which were then embedded into the matrix of ODTs. The particle sizes displayed good elastic properties with low Young's modulus (YM) values, and there was no significant difference between the different sizes (45, 60, 93 µm; p > 0.05). The tensile strength of the pellets was directly proportional to YM (p < 0.05), providing enough support to maintain their integrity under compression. Pellets made from 63 µm Eudragit L100 had a suitable balance of mechanical and pharmaceutical properties compared to other sizes. 63 µm pellets had an aspect ratio of 1.49 ± 0.26 and 61% yield, while their ODTs showed a fast disintegration time of 14 ± 0.6 s, while modifying the drug release. Furthermore, IND exhibited modified release in acidic media (pH 1.2) and immediate release in buffer media (pH 6.8). Overall, protecting pellet integrity was crucial to delay release in acidic media and enable immediate release in alkaline media. The newly developed formulation will improve compliance and reduce side effects associated with IND and other irritant drugs particularly in elderly populations.
Keywords: Delayed release; Eudragit L100; Indomethacin; Orally disintegrating tablets; PH-dependent polymers; Pellets.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of Interest: The author declares no conflict of interest.
References
-
- Emam Kassab, S. Indomethacin from Anti-Inflammatory to Anticancer Agent. In Medicinal Chemistry; IntechOpen, 2019.
-
- Ikawa Y, Fujino H, Otake S, Murayama T. Indomethacin Antagonizes EP2 Prostanoid Receptor Activation in LS174T Human Colon Cancer Cells. Eur J Pharmacol. 2012;680:16–21. https://doi.org/10.1016/j.ejphar.2012.01.033 . - DOI
-
- Hawkins C, Hanks GW. The Gastroduodenal Toxicity of Nonsteroidal Anti-Inflammatory Drugs. A Review of the Literature. J Pain Symptom Manage. 2000;20:140–51. - DOI
-
- CMS-Updates Non-Steroidal Anti-Inflammatory Drugs and Serious Gastrointestinal Adverse Reactions-1. Br Med J 1986;292:614.
-
- Roth SH. NSAID Gastropathy: A New Understanding. Arch Intern Med. 1996;156:1623–8. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
